GlassScriptPhysician profile
Stacey L Galowitz
NPI 1972825719
$11,825.79
in general payments reported to CMS, 2019-2025
21 companies · $7,997 in 2025
The $7,997 reported for 2025 was more than what 87% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $703 · 2020: $568 · 2021: $828 · 2022: $707 · 2023: $775 · 2024: $247 · 2025: $7,997.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,825 · Food and Beverage: $2,648 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,000 · Travel and Lodging: $512 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,825.00 |
| Food and Beverage | $2,647.72 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,000.00 |
| Travel and Lodging | $512.02 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $4,783.74 | 2022-2025 | Xolair |
| Ars Pharmaceuticals Operations, INC. | $2,144.88 | 2025 | Neffy |
| Genzyme Corporation | $1,366.86 | 2019-2025 | |
| Alk-Abello, INC | $738.75 | 2019-2023 | Ragwitek, Grastek, Odactra |
| Regeneron Healthcare Solutions, INC. | $694.01 | 2019-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $556.54 | 2019-2025 | Airsupra, Tezspire |
| Glaxosmithkline, LLC. | $461.24 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Incyte Corporation | $217.63 | 2021-2025 | Opzelura |
| Kaleo, INC. | $192.87 | 2019-2024 | Auvi-Q |
| Leo Pharma INC. | $139.02 | 2025 | Anzupgo |
| Optinose US, INC. | $136.51 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $110.53 | 2019-2025 | |
| Intuity Medical INC | $69.24 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
| Takeda Pharmaceuticals U.S.A., INC. | $43.33 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $35.86 | 2019-2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $34.00 | 2025 | |
| Shire North American Group INC | $29.25 | 2019 | |
| Pfizer INC. | $27.70 | 2020 | |
| Organon LLC | $16.55 | 2025 | Vtama |
| Paratek Pharmaceuticals, INC. | $15.39 | 2025 | Xhance |
| Aimmune Therapeutics, INC. | $11.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacey Galowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.